...
首页> 外文期刊>Neurochemistry International: The International Journal for the Rapid Publication of Critical Reviews, Preliminary and Original Research Communications in Neurochemistry >Inhibitors of catecholamine metabolizing enzymes cause changes in S-adenosylmethionine and S-adenosylhomocysteine in the rat brain.
【24h】

Inhibitors of catecholamine metabolizing enzymes cause changes in S-adenosylmethionine and S-adenosylhomocysteine in the rat brain.

机译:儿茶酚胺代谢酶的抑制剂引起大鼠大脑中S-腺苷甲硫氨酸和S-腺苷同型半胱氨酸的变化。

获取原文
获取原文并翻译 | 示例
           

摘要

Previous studies have shown that the biochemical changes that occur in parkinsonism are associated with disturbances in methylation reactions. Therefore, our hypothesis was that MAO and COMT inhibitors, which inhibit the metabolism of dopamine, might affect the methylation reaction. In the present study, we analyzed levels of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in brain homogenates from rats which had received a one-week treatment with tolcapone or phenelzine, inhibitors of COMT and MAO, respectively. Tolcapone treatment caused an increase in the levels of SAM (130% as compared with control animals, p < 0.001). In animals treated with phenelzine, the SAM levels were 78% of those of the controls (p < 0.05). SAH levels were slightly increased (115% as compared with controls, p < 0.05) in the phenelzine group, while they were unchanged in the tolcapone treated animals. Treatment with tolcapone decreased the catalytic activity of methionine adenosyltransferase (MAT) (from 15.4 +/- 1.6 to 11.3 +/- 1.4 pmol mg-1 min-1, p < 0.0001) while phenelzine treatment had no significant effect. In addition the transmethylation ratio (SAM/SAH) were significantly increased with tolcapone (120%, p < 0.05) and decreased with phenelzine (71%, p < 0.05) as compared to the controls. The essential finding of this paper was that brain SAM levels were reduced by MAO inhibition and enhanced by COMT inhibition.
机译:先前的研究表明,帕金森氏症中发生的生化变化与甲基化反应的紊乱有关。因此,我们的假设是抑制多巴胺代谢的MAO和COMT抑制剂可能会影响甲基化反应。在本研究中,我们分析了大鼠均质的脑匀浆中S-腺苷甲硫氨酸(SAM)和S-腺苷同型半胱氨酸(SAH)的水平,分别接受了tolcapone或phenelzine分别为COMT和MAO的抑制剂治疗。托卡朋处理导致SAM水平升高(与对照动物相比,为130%,p <0.001)。在用苯乙嗪治疗的动物中,SAM含量是对照组的78%(p <0.05)。苯乙嗪组的SAH水平略有升高(与对照组相比,为115%,p <0.05),而在托卡朋处理的动物中,SAH水平没有变化。托卡朋处理可降低甲硫氨酸腺苷基转移酶(MAT)的催化活性(从15.4 +/- 1.6降至11.3 +/- 1.4 pmol mg-1 min-1,p <0.0001),而苯乙嗪处理则无明显效果。此外,与对照相比,甲苯磺隆(120%,p <0.05)显着提高了甲基化率(SAM / SAH),而苯乙嗪(71%,p <0.05)则显着降低了甲基化率。这篇论文的基本发现是,脑SAM水平通过MAO抑制而降低,而通过COMT抑制而提高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号